• Je něco špatně v tomto záznamu ?

The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease

V. Hepnarova, J. Korabecny, L. Matouskova, P. Jost, L. Muckova, M. Hrabinova, N. Vykoukalova, M. Kerhartova, T. Kucera, R. Dolezal, E. Nepovimova, K. Spilovska, E. Mezeiova, NL. Pham, D. Jun, F. Staud, D. Kaping, K. Kuca, O. Soukup,

. 2018 ; 150 (-) : 292-306. [pub] 20180302

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024307

Novel tacrine-benzyl quinolone carboxylic acid (tacrine-BQCA) hybrids were designed based on multi-target directed ligands (MTLDs) paradigm, synthesized and evaluated in vitro as inhibitors of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE). Tacrine moiety is represented herein as 7-methoxytacrine, 6-chlorotacrine or unsubstituted tacrine forming three different families of seven members, i.e. 21 compounds in overall. Introducing BQCA, a positive modulator of M1 muscarinic acetylcholine receptors (mAChRs), the action of novel compounds on M1 mAChRs was evaluated via Fluo-4 NW assay on the Chinese hamster ovarian (CHO-M1WT2) cell line. All the novel tacrine-BQCA hybrids were able to block the action of hAChE and hBChE in micromolar to nanomolar range. The hAChE kinetic profile of 5p was found to be mixed-type which is consistent with our docking experiments. Moreover, selected ligands were assessed for their potential hepatotoxicity on HepG2 cell line and presumable permeation through the blood-brain barrier by PAMPA assay. Expected agonistic profile towards M1 mAChRs delivered by BQCA moiety was not confirmed. From all the hybrids, 5o can be highlighted as non-selective cholinesterase inhibitor (hAChE IC50 = 74.5 nM; hBChE IC50 = 83.3 nM) with micromolar antagonistic activity towards M1 mAChR (IC50 = 4.23 μM). A non-selective pattern of cholinesterase inhibition is likely to be valuable during the onset as well as later stages of AD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024307
003      
CZ-PrNML
005      
20221014092210.0
007      
ta
008      
180709s2018 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2018.02.083 $2 doi
035    __
$a (PubMed)29533874
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Hepnarova, V $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic; Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
245    14
$a The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease / $c V. Hepnarova, J. Korabecny, L. Matouskova, P. Jost, L. Muckova, M. Hrabinova, N. Vykoukalova, M. Kerhartova, T. Kucera, R. Dolezal, E. Nepovimova, K. Spilovska, E. Mezeiova, NL. Pham, D. Jun, F. Staud, D. Kaping, K. Kuca, O. Soukup,
520    9_
$a Novel tacrine-benzyl quinolone carboxylic acid (tacrine-BQCA) hybrids were designed based on multi-target directed ligands (MTLDs) paradigm, synthesized and evaluated in vitro as inhibitors of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE). Tacrine moiety is represented herein as 7-methoxytacrine, 6-chlorotacrine or unsubstituted tacrine forming three different families of seven members, i.e. 21 compounds in overall. Introducing BQCA, a positive modulator of M1 muscarinic acetylcholine receptors (mAChRs), the action of novel compounds on M1 mAChRs was evaluated via Fluo-4 NW assay on the Chinese hamster ovarian (CHO-M1WT2) cell line. All the novel tacrine-BQCA hybrids were able to block the action of hAChE and hBChE in micromolar to nanomolar range. The hAChE kinetic profile of 5p was found to be mixed-type which is consistent with our docking experiments. Moreover, selected ligands were assessed for their potential hepatotoxicity on HepG2 cell line and presumable permeation through the blood-brain barrier by PAMPA assay. Expected agonistic profile towards M1 mAChRs delivered by BQCA moiety was not confirmed. From all the hybrids, 5o can be highlighted as non-selective cholinesterase inhibitor (hAChE IC50 = 74.5 nM; hBChE IC50 = 83.3 nM) with micromolar antagonistic activity towards M1 mAChR (IC50 = 4.23 μM). A non-selective pattern of cholinesterase inhibition is likely to be valuable during the onset as well as later stages of AD.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a Alzheimerova nemoc $x farmakoterapie $x metabolismus $7 D000544
650    _2
$a zvířata $7 D000818
650    _2
$a butyrylcholinesterasa $x metabolismus $7 D002091
650    _2
$a buněčné linie $7 D002460
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
650    _2
$a Cricetulus $7 D003412
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a lidé $7 D006801
650    _2
$a molekulární struktura $7 D015394
650    _2
$a chinoliny $x chemie $x farmakologie $7 D011804
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a takrin $x chemie $x farmakologie $7 D013619
655    _2
$a časopisecké články $7 D016428
700    1_
$a Korabecny, J $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic; Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Matouskova, L $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic.
700    1_
$a Jost, P $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic; Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Muckova, L $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic.
700    1_
$a Hrabinova, M $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic; Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Vykoukalova, N $u Department of Pharmacology and Toxicology, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Kerhartova, M $u Department of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Kucera, T $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic.
700    1_
$a Dolezal, R $u Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Nepovimova, E $u Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03, Hradec Kralove, Czech Republic.
700    1_
$a Spilovska, K $u Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic.
700    1_
$a Mezeiová, Eva $u Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic. $7 xx0277560
700    1_
$a Pham, N L $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic; Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Jun, D $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01, Hradec Kralove, Czech Republic; Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Staud, F $u Department of Pharmacology and Toxicology, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.
700    1_
$a Kaping, D $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic.
700    1_
$a Kuca, K $u Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03, Hradec Kralove, Czech Republic.
700    1_
$a Soukup, O $u Biomedical Research Centre, University Hospital, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. Electronic address: ondrej.soukup@fnhk.cz.
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 150, č. - (2018), s. 292-306
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29533874 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20221014092203 $b ABA008
999    __
$a ok $b bmc $g 1316438 $s 1021228
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 150 $c - $d 292-306 $e 20180302 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace